Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.

Title: Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.
Authors: Nicolas, C.; Domas, Q.; Pol, S.; Bardou-Jacquet, E.; Loustaud-Ratti, V.; Métivier, S.; Asselah, T.; Thabut, D.; Bourlière, M.; Mathurin, Philippe; Foucher, J.; Larrey, D.; Varaut, A.; Alric, L.; Bailly, F.; Muti, L.; Buchard, B.; Abergel, A.
Contributors: Université de Lille; Inserm; CHU Lille; Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Publication Year: 2025
Collection: LillOA (Lille Open Archive - Université de Lille)
Subject Terms: direct-acting antiviral; genotype 5; hepatitis C virus; real-world; sustained virological response
Description: Background: Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%. Methods and results: Here we evaluated sustained virological response at week 12 post-treatment (SVR12) in 147 HCV-GT-5 patients from 14 French university hospitals (2014-2021) treated with direct-acting antivirals (DAA) in real-life. Patients had mainly received sofosbuvir/ledipasvir ± ribavirin, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir. Overall SVR12 was 98% (144/147). Two patients experienced relapse: one was successfully retreated with the same DAAs (sofosbuvir/ledipasvir) plus ribavirin, and the other refused further DAA treatment. One patient with virological failure (sofosbuvir/velpatasvir) had received a second treatment (sofosbuvir/velpatasvir/voxilaprevir) and progressed to cure. Conclusions: HCV-GT-5 patients treated with a DAA regimen had a 99% SVR12 in intention-to-treat (including initial therapy and retreatment) and 100% SVR12 per protocol. Sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir show very good efficacy in real-world HCV-GT-5 patients. ; 45;4
Document Type: article in journal/newspaper
Language: English
Relation: Liver Int; https://hdl.handle.net/20.500.12210/129532
Availability: https://hdl.handle.net/20.500.12210/129532
Rights: info:eu-repo/semantics/closedAccess
Accession Number: edsbas.6074C689
Database: BASE